目的 觀察芪骨膠囊聯(lián)合注射用重組特立帕肽治療骨質(zhì)疏松癥的臨床療效。方法 選取2020年1月—2021年3月南陽醫(yī)學(xué)高等?？茖W(xué)校第一附屬醫(yī)院收治的111例骨質(zhì)疏松癥患者，根據(jù)治療方案的不同將所有患者分為對照組（54例）和治療組（57例）。對照組患者大腿或腹部皮下注射注射用重組特立帕肽，20μg/次，1次/d。治療組患者在對照組的基礎(chǔ)上口服芪骨膠囊，3粒/次，3次/d。28d為1個(gè)療程，共治療6個(gè)療程。觀察兩組的臨床療效，比較兩組的不同部位骨密度、骨吸收和骨形成指標(biāo)。結(jié)果 治療后，治療組的總有效率為94.74%，高于對照組患者的總有效率77.78%，組間比較差異顯著（P<0.05）。治療后，兩組腰椎L_2～4、股骨頸、橈骨遠(yuǎn)端1/3處的骨密度均較治療前升高（P<0.05），且治療后治療組的腰椎L_2～4、股骨頸、橈骨遠(yuǎn)端1/3處的骨密度高于對照組（P<0.05）。治療后，兩組血清Ⅰ型原膠原C-端前肽（PICP）、骨特異性堿性磷酸酶（BALP）、骨鈣素（BGP）水平均較治療前升高（P<0.05），且治療后，治療組的血清PICP、BALP、BGP水平高于對照組（P<0.05）。治療后，兩組血清抗酒石酸酸性磷酸酶（TRACP）、Ⅰ型膠原C-末端肽交聯(lián)（S-CTX）水平均較治療前下降（P<0.05），且治療后治療組的血清TRACP、S-CTX水平低于對照組（P<0.05）。結(jié)論 芪骨膠囊聯(lián)合注射用重組特立帕肽治療骨質(zhì)疏松癥具有較好的臨床療效，可有效改善機(jī)體骨密度，調(diào)節(jié)血清PICP、BALP、BGP、TRACP、S-CTX水平。

ObjectiveTo observe the clinical therapeutic effect of Qigu Capsules combined with Recombinant Teriparatide for injection in treatment of osteoporosis. MethodsPatients (111 cases) with osteoporosis in the First Affiliated Hospital of Nanyang Medical College from January 2020 to March 2021 were divided into the control group (54 cases) and the treatment group (57 cases) according to different treatment plans. Patients in the control group were sc administered with Recombinant Teriparatide for injection in thigh or abdomen, 20 μg/time, once daily. Patients in the treatment group were po administered with Qigu Capsules on the basis of the control group, 3 grains/time, three times daily. A course of treatment had 28 d, and patients in two groups were treated for 6 courses. After treatment, the clinical efficacies were evaluated, and the bone density in different parts, bone resorption and bone formation markers in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.74%, which was higher than that (77.78%,) of the control group, with a significant difference between two groups (P < 0.05). After treatment, the bone mineral density of lumbar vertebra L_{2— 4}, femoral neck, and distal 1/3 of radius in two groups were increased compared with those before treatment (P < 0.05), and after treatment, the bone mineral density of lumbar vertebra L_{2— 4}, femoral neck, and distal 1/3 of radius in treatment group was higher than that in the control group (P < 0.05). After treatment, the serum levels of PICP, BALP, and BGP in two groups were higher than those before treatment (P < 0.05), and after treatment, the serum levels of PICP, BALP, and BGP in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of TRACP and S-CTX in two groups were decreased compared with those before treatment (P < 0.05). And after treatment, the serum levels of TRACP and S-CTX in the treatment group were lower than those in the control group (P < 0.05). Conclusion Qigu Capsules combined with Recombinant Teriparatide for injection has clinical curative effect in treatment of osteoporosis, can effectively improve the body’s bone mineral density and regulate the serum levels of PICP, BALP, BGP, TRACP, and S-CTX.

R982

河南省科技計(jì)劃項(xiàng)目（182102310466）